Morning Medical with Dr. Chow
A daily update covering the latest medical & health news from around the world using artificial intelligence. Doctor Chi-Ming Chow is a family physician, general internist, and cardiologist. He is also a Professor of Medicine at the University of Toronto.
Walking, GLP-1 Nail Risks, New Weight Loss Therapies, and Type 2 Diabetes
In this episode, Dr. Chi-Ming Chow discusses how walking may support longevity, then looks at possible nail disorder risks with GLP-1 medications and the importance of monitoring nail health during treatment. He also reviews new weight loss therapies for type 2 diabetes, including clinical trial design, side effects, and next steps. The episode closes with a discussion of a petition calling for health supports for residential school survivors and a proposal to criminalize denialism.
Key Points
- Walking more and especially walking at a brisk pace is linked to lower mortality, with the greatest benefit seen around 7,500 to 10,000 steps per day.
- GLP 1 receptor agonists may be associated with nail changes such as onycholysis and discoloration, so new nail symptoms in patients taking these drugs should be assessed.
- The combination of eloralintide and tirzepatide produced substantial weight loss and strong glucose control in type 2 diabetes, but higher doses also caused more side effects and treatment discontinuation.
Chapters
| 0:00 | |
| 2:31 | |
| 4:28 | |
| 5:54 | |
| 8:33 | |
| 9:21 |
Transcript
Loading transcript...
- / -